Study on Effect of Benzbromarone in the Patients with Gout.
- Author:
Seong Hoon HAN
1
;
Hong Joon AHN
;
Dong Wook KIM
;
Yun Woo LEE
Author Information
1. Department of Internal Medicine, College of Medicine, Inje University, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Benzbromarone;
Gout
- MeSH:
Benzbromarone*;
Blood Cell Count;
Creatinine;
Europe;
Exanthema;
Gout*;
Humans;
Korea;
Liver Function Tests;
Plasma;
Uric Acid
- From:The Journal of the Korean Rheumatism Association
1999;6(3):203-208
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: Benzbromarone is a most potent uricosuric agent which has been marketed in Europe. The purpose of this study was to evaluate the safety and efficacy of benzbromarone as a uric acid lowering agent in gouty patients in Korea. METHOD: Twenty-one patients with gout, who were lower excreter of uric acid and had no other complication of gout, were treated with benzbromarone for 6 months. In these patients we checked complete blood count, liver function test, BUN, creatinine, serum uric acid, 24 hour urine uric acid excretion and uric acid clearance before and after treatment with benzbromarone. RESULTS: Significant improvements(p<0.01) were found in the serum uric acid level, 24h uric acid excretion and uric acid clearance. The mean serum uric acid decreased from 8.2mg/dl to 5.1mg/dl at the end of 6 months; mean urinary uric acid excretion increased from 425.9mg/day to 760.3mg/day; and the uric acid clearance increased from 3.5mL/min to 10.9mL/min. There are no clinical or laboratory side effects, except skin rash in the one patient. CONCLUSION: Benzbromarone was effective to control plasma uric acid concentration at doses ranging from 25 to 50mg/day.
